Search by Drug Name or NDC
NDC 51655-0593-26 Nifedipine 30 mg/1 Details
Nifedipine 30 mg/1
Nifedipine is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Northwind Pharmaceuticals, LLC. The primary component is NIFEDIPINE.
MedlinePlus Drug Summary
Nifedipine is used to treat high blood pressure and to control angina (chest pain). Nifedipine is in a class of medications called calcium-channel blockers. It lowers blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. It controls chest pain by increasing the supply of blood and oxygen to the heart. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 51655-0593-26Last Updated: 04/21/2024
MedLinePlus Full Drug Details: Nifedipine
Product Information
| NDC | 51655-0593 |
|---|---|
| Product ID | 51655-593_f32c1aa0-d9f7-9802-e053-2995a90a3223 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | Nifedipine |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | nifedipine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 30 |
| Active Ingredient Units | mg/1 |
| Substance Name | NIFEDIPINE |
| Labeler Name | Northwind Pharmaceuticals, LLC |
| Pharmaceutical Class | Calcium Channel Antagonists [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA210614 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 51655-0593-26 (51655059326)
| NDC Package Code | 51655-593-26 |
|---|---|
| Billing NDC | 51655059326 |
| Package | 90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (51655-593-26) |
| Marketing Start Date | 2023-01-03 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |